SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Nanobiotix reports response rate in Phase 1 melanoma study

Nanobiotix reported a response rate in a Phase 1 study involving resistant melanoma.

Related stories